The sam® breakthrough technology accelerates athletes' soft tissue healing and recovery time through long-duration ultrasound treatment
TRUMBULL, Conn., March 21, 2023 (Newswire.com)
-
As proud 2023-2024 platinum sponsors of the Professional Football Athletic Trainer's Society (PFATS), ZetrOZ Systems will demonstrate its sam® 2.0 and sam® x1 units at an honor reception on Tuesday, March 21, at Wild Horse Pass in Phoenix.
ZetrOZ Systems will present clinical data and scientific studies from the past year on the efficacy of sustained acoustic medicine and its injury-healing potential at the PFATS Honors Reception to be held on March 21 from 6-9 p.m. in the Akimel Ballroom of the Sheraton Grand.
Dr. George Lewis, founder and CEO of ZetrOZ Systems, will be a guest speaker for the Membership Presentation the following morning, 9:50-10:10 a.m.
PFATS provides the highest quality of healthcare to the National Football League and works closely with the NFL Physician Society, National Football League (NFL), and the National Athletic Trainers Association (NATA). It elevates athletic training through research and education to its diverse, 158-plus members across the country, with many of them holding advanced degrees, specialty certifications, and being Certified Athletic Trainers (ATC).
"We're proud to contribute our breakthrough sam® product innovation to PFATS's arsenal of athlete care," Dr. Lewis said. "ZetrOZ Systems works with athletes on all NFL teams — to that end, we're launching a new player performance program that's built around healing daily micro-trauma as an injury prevention measure."
Some of the most common injuries ZetrOZ members face include high-ankle sprains, hamstring tears, and contusions. While, traditionally, athletes have had to navigate injuries and pain management with medication or even surgery, sustained acoustic medicine has been clinically proven by over 40 studies as a non-invasive alternative.
The sam® 2.0 and sam® X1 wearable ultrasound devices are the only FDA-cleared units of their kind and can be used daily at home for injury healing, joint pain, and more. By increasing oxygen flow, the removal of cellular waste, and stimulating regeneration, sam® devices boost the body's natural healing propensities, speeding up the recovery process and getting athletes back in action as quickly as possible. With research funded and backed by the National Institutes of Health, National Science Foundation, Department of Defense, NASA, and more, ZetrOZ Systems has risen as an industry leader in soft tissue healing.
To learn more about ZetrOz Systems, visit zetroz.com.
About ZetrOZ Systems
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.
Partnership Will Digitize Delivery of Workplace Wellness Programs and Reduce Cost of Injuries
ATLANTA, March 21, 2023 (Newswire.com)
-
In a new deal announced this week, Work Right NW, a nationally recognized leader in injury prevention and human performance, will deploy AMP's cloud-based software platform to clients nationwide.
Work Right NW delivers innovative injury prevention and workplace wellness programs to corporate partners seeking to proactively address employee health. Utilizing licensed Athletic Trainers and Physical Therapists as onsite Injury Prevention Specialists, Work Right NW delivers an integrated and comprehensive model that targets overall safety and wellness. By providing for the wellness of their employees prior to the development of injury, corporations are able to substantially reduce the cost of workplace injuries, lower non-occupational medical costs, improve employee morale, and increase efficiency.
"With an expanding roster of Fortune 500 clients requiring more rigorous supply chain sustainability strategies, we knew it was time to leverage the latest in enterprise grade technology and analytics," says Work Right NW Founder and CEO Nic Patee. "Our industrial customers expect our services to be timely, engaging, and transparent in terms of performance and outcomes. AMP puts us in lockstep with these next-generation workflows and care methodologies. We are excited to help them iterate on new features that will further our mission to innovate in this space."
Originally built with the best sports scientists and sports medicine practitioners to prepare elite athletes for competition, AMP now empowers employee service providers with the risk management and cost containment tools necessary to adopt a proactive stance to overall worker health and wellbeing. An enterprise platform that scales to fit organizations of all sizes, it is customizable to suit a range of industries looking to engage employees in programs to keep them safe, strong, and productive. Working with elite partners to solve big problems in challenging environments is central to AMP's mission.
"In early discussions with Nic and his team, we felt their need to not only scale operationally but to further modernize, centralize, and standardize their intellectual property and industry-leading service offerings," explains AMP CEO David Nichols. "Today's industrial employer is placing a premium on employee retention, durability and emotional wellbeing. AMP's platform will continue to help Work Right NW check those boxes all while maintaining their preventative, data-driven approach to quality care. We're thrilled about this new relationship with Work Right NW. It will put us on the frontlines of Industrial Athletic performance and allow us to continue to develop purpose-driven functionality to better serve employers and their workforces."
Contact Information:
Richard Walsh
CRO [email protected]
+16783678187
PARIS, March 21, 2023 (Newswire.com)
-
SFD 2023 - Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk. The agreement covers integrating DBL-4pen™, Diabeloop's self-learning algorithm for MDI therapy, with Novo Nordisk's connected and reusable insulin pens, NovoPen® 6 and NovoPen Echo® Plus.
Diabeloop is planning a dedicated study for people living with Type 2 diabetes to evaluate the efficacy and clinical benefits of the combined technologies.
Diabeloop accelerates its interoperability strategy with connected pens
On the occasion of the annual congress of the Société francophone du diabète (SFD), in Montpellier, March 21-24, Diabeloop announces a collaboration with Novo Nordisk, a major global healthcare company.
The first milestone of the cooperation will focus on the integration of Novo Nordisk's new generation of connected pens, NovoPen® 6 and NovoPen Echo® Plus with DBL-4pen™.
DBL-4pen™ is a self-learning basal and bolus recommendation app for people with Type 1 and Type 2 diabetes who take multiple daily insulin injections (MDI). NovoPen® 6 and NovoPen Echo® Plus are connected pens with a dose memory function that keeps a history of the last 800 insulin injections and shows on a built-in digital display the number of units administered during the last injection, as well as the time since that injection. Data transfer from the connected pen to an external device is based on Near Field Communication (NFC). These connected pens are the only to be covered by public health insurance in France.
The common commitment of the two companies to bring innovative solutions for diabetes management to patients has driven the conclusion of this agreement.
"We are proud to be able to further expand our DBL-4pen™ interoperability strategy with this collaboration with Novo Nordisk. Our collaboration aims to bring more automated solutions to people with diabetes, optimizing their outcomes and improving their quality of life. With DBL-4pen™, we have developed an efficient self-learning algorithm for insulin dose recommendation, a significant step forward for MDI therapy, and we are excited to explore this with the innovative generation of NovoPen® 6 and NovoPen Echo® Plus connected insulin pens," explains Cécile Ferracci, CCO of Diabeloop.
Upcoming launch of a clinical program with Type 2 diabetes patients
The clinical program will start with an initial multi-brand, multicentric before/after 14-week clinical trial that aims to assess the efficacy and safety of DBL-4pen™ mobile application on glycemic control in patients with Type 2 diabetes. It will include forty (40) patients with T2D across four (4) hospitals in France.
Pr. Pierre-Yves Benhamou, Chief Medical Officer of Diabeloop, comments: "With this interventional, open, single-arm clinical trial involving adults with Type 2 diabetes, we aim to evaluate efficacy, safety and also treatment compliance. In addition, we will measure the improvement in quality of life and satisfaction of the enrolled patients and also evaluate the effect of DBL-4pen™on the development of HbA1c in the extension phase."
Diabeloop will then initiate a dedicated clinical study, to assess the efficacy and the clinical benefits of the combined solution connecting DBL-4pen™ with NovoPen® 6 and NovoPen Echo® Plus connected pens. NovoPen® 6 and NovoPen Echo® Plus data will transmit to the DBL-4penTM self-learning algorithm which will recommend the dose of insulin to be injected in real-time from input data such as meals and exercise.
This trial program is shaping Diabeloop's future projects for MDI therapy. Diabeloop plans to address first the Type 2 population on intensive insulin treatment before soon expanding to people with Type 1 diabetes who do not have access to or desire to wear an insulin pump.
"We are delighted about this collaboration with Diabeloop - a company that has a shared ambition of bringing innovative digital health solutions to help people manage their diabetes," says Thomas Thestrup-Terp, Corporate Vice President, Digital Strategy and Solutions, Novo Nordisk. "Smart insulin pens offer digital connectivity for people living with diabetes and the potential to automatically recommend the ideal insulin dose in real-time. This could significantly improve the way diabetes medicines are used. We look forward to the data from the upcoming clinical study, to look at the potential benefits of NovoPen® 6 and NovoPen Echo® Plus alongside DBL-4pen™."
"Novo Nordisk France is pleased to support Diabeloop, a French company that has developed the first 'closed-loop' solution for patients treated with MDI. Novo Nordisk is thus supporting a game-changing company, in order to accelerate the CE marking of its new solution. We look forward to providing patients with a reliable solution that will take the NovoPen® 6 and NovoPen Echo® Plus from connected to smart reusable insulin pens," adds Christine Massien, Diabetes Medical Director within Novo Nordisk France.
DBL-4pen™, self-learning basal and bolus recommendation app for pen users
Diabeloop has developed a unique smartphone app that embeds its self-learning algorithm to dynamically titrate basal and bolus insulin doses. The app is connected to a connected insulin pen and a continuous glucose monitor (CGM).
This solution reaches a high level of personalization, taking into account both meals and physical activities, as well as glucose trends, and uses the entire patient history to fine-tune bolus amounts based on the patient's response to previous boluses. Requiring minimal input from users, DBL-4pen™ automatically recommends the ideal insulin dose in real time, which can be delivered via the pen with no more calculation to do.
"DBL-4pen™ can significantly contribute to improving clinical outcomes and reduce the huge mental burden for people living with Type 1 and Type 2 diabetes. Diabeloop's mission and goal has always been to provide more solutions to people with diabetes. The combination of connected pens with Diabeloop's self-learning algorithm gives us the opportunity to offer more choice to the patients and bring the power of self-learning algorithms to more affordable and accessible pen solutions," concludes Erik Huneker, CEO of Diabeloop.
About Diabeloop
Diabeloop's mission: Making innovation accessible to people living with diabetes, improving clinical results while relieving them of their constant mental burden.
Created in 2015, Diabeloop offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop's first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.
Diabeloop completed its Series C financing round in June 2022, securing 70 million euros, to accelerate its commercial roll-out, support its sustained growth strategy and its high-impact projects.
Today, Diabeloop gathers the personality, passion, and skills of talented individuals who work hard to improve the quality of life for every person living with diabetes.
Contact Information:
Stéphanie JÉGU
Global Brand & Communication Director, Diabeloop [email protected]
On the JoBlo Movies YouTube channel, we will be posting one full movie every other day throughout the week, giving viewers the chance to watch them entirely free of charge. Today’s Free Movie of the Day is the thriller Harm’s Way, starring Kathleen Quinlan. You can watch it over on the YouTube channel linked above, or you can just watch it in the embed at the top of this article.
Directed by Melanie Orr from a screenplay by William Tyler Bell, Harm’s Way has the following synopsis: The proprietor of a women’s shelter jeopardizes the relationship between an abused mother and daughter. Darlene and her daughter Victoria seek refuge at a remote rural safe house for abused women that’s run by the strict and tough, but folksy and supportive Bea. Things turn sour when Bea proves to be a total lunatic with an especially dangerous influence on the impressionable Victoria.
Quinlan is joined in the cast by Ingrid Kavelaars, Hannah Lochner, Claudia Wit, Dan Petronijevic, David Sparrow, Jeff Topping, and Arlene Mazerolle.
Orr got her start working in the entertainment industry as a script supervisor in 2001, then made her feature directorial debut with the horror film Grindstone Road in 2008. Harm’s Way was her second feature. Since then, Orr has directed The Devil’s Mercy and episodes of the shows Forbidden Science, Scare Tactics, Dark Matter, The Next Step, Bajillionaires, Dino Dana, Utopia Falls, Ghostwriter, Children Ruin Everything, Spencer Sisters, and The Hardy Boys, among others. Orr has also worked as a second unit director and cinematographer.
So take a look at Harm’s Way – it’s free! – then let us know what you thought of it by leaving a comment below or on the YouTube page.
The movies that have previously been featured as the Free Movies of the Day can be found at THIS LINK, and also on the JoBlo Movies YouTube channel.
WARNING: BIG SPOILERS FOR SHAZAM: FURY OF THE GODS IN THIS ARTICLE
WARNING: BIG SPOILERS FOR SHAZAM: FURY OF THE GODS BELOW . . . .
Well, in a curious move from the marketing department at Warner Bros., a new TV spot for Shazam: Fury of the Godsshowcases a pretty big cameo reveal. CBR reports on the TV spot spoiler and director David F. Sandberg’s reaction (although they also put the spoiler in the url, so tread carefully).
Amid the shake-ups and reinvention of the DC Film universe, with James Gunn and Peter Safran spearheading a ten-year plan, some of the existing franchise sequels are still scheduled for release, including Aquaman and the Lost Kingdom and The Flash. However, Shazam: Fury of the Gods is set to release later this month and promotion is already up and running. This includes at least one TV spot that spoils a cameo appearance that would have surely excited some of the fans and garner applause at the theater. Although, it still might, depending upon who has seen the commercial.
In one of the TV spots for the film, there is not only a shot but an extended exchange between Shazam and Wonder Woman, played once again by Gal Gadot, as she appears to help bail him out of a jam. This is an official release and not leaked clip. The director of the Shazam movies, David F. Sandberg, has addressed this on Twitter with a post saying, “Well there’s some big Shazam spoilers out there now. If you want to go in fresh maybe don’t be online or watch tv with ads… Pretty good advice in general actually.”
Zachary Levi, the film’s star, would quote the director’s tweet as he backs it with his post simply saying, “THISSSSSSS!!!” One of the big perks of having a shared universe is being able to crossover characters from one movie to the next, and these sequels usually play their cards when they can. What will particularly be a bummer for fans is this may be the last time we see Gal Gadot in the role after her four film appearances. Plans for a third Wonder Woman had fallen through as controversy around Patty Jenkins’ departure led to the project’s demise.
Shazam: Fury of the Gods is due to zap into theaters on March 17.
By the way, I must say in Sideshow Bob-like fashion, I’m well aware of the irony of posting the spoiler in reporting that the director advises fans to stay away from spoilers.
Dwayne Johnson weighs in on fighting to bring Henry Cavill back to the DCU, only to have his role cut by new studio management.
While cruising the red carpet in his sharp salmon-colored suit at last night’s Academy Awards celebration, Dwayne Johnson got real about Henry Cavill’s exit from the DCU. While smiling for the cameras, Variety‘s senior culture and events editor Marc Malkin asked Johnson about his feelings toward Cavill’s big comeback getting ditched by the studio’s new management.
“All that I can do, and all that we could do when we were making ‘Black Adam,’ was to put our best foot forward and surround ourselves with the best people and deliver the best movie we could,” Johnson said. “Our audience score was in the 90s. Critics took a couple shots, but that’s just the business of it.”
“It’s almost like when you have a pro football team and your quarterback wins championships and your head coach wins championships and then a new owner comes in and says, ‘Not my coach, not my quarterback. I’m going to go with somebody new.’”
One of the highlights of Black Adam involves Black Adam (Dwayne Johnson) being confronted by Superman (Henry Cavill), with the Man of Steel warning the anti-hero about stepping out of line. The moment suggests a clash between the two titans is forthcoming. However, with James Gunn and Peter Safran now in charge of the studio, the battle between the two omega-level punching bags has been postponed indefinitely.
It’s hard to imagine a world where Johnson isn’t bitter about Gunn and Safran taking DC Studios in a new direction. Johnson tried for 15 years to get Black Adam into theaters, promising fans a changing of the hierarchy at DC with the anti-hero’s arrival. Unfortunately, Black Adam underperformed at the box office, bringing the character’s future at the studio into question.
“After 15 years of relentless hard work to finally make ‘Black Adam,’ I’m very proud of the film we delivered for fans worldwide. I will always look back on the fan reaction to ‘Black Adam’ with tremendous gratitude, humility and love,” Johnson told fans last December.
Johnson insists he and James Gunn are in touch and that Black Adam has a future at the studio. “James Gunn and I connected, and Black Adam will not be in their first chapter of storytelling. However, DC and Seven Bucks have agreed to continue exploring the most valuable ways Black Adam can be utilized in future DC multiverse chapters.”
Do you think Black Adam will appear in the DCU at any point? Will Cavill’s Superman return to the DCU as part of a multiversal storyline? Feel free to let us know what you think in the comments below.
Evolve Med Spa celebrates its one-year anniversary on Thursday, March 23, with an all-day event featuring raffles, gifts and exclusive promotions on body contouring, laser hair removal, injectables and skin rejuvenation.
RED BANK, N.J., March 20, 2023 (Newswire.com)
-
Evolve Med Spa, an award-winning destination for aesthetic services, announced an event on Thursday, March 23, 2023, from 10am to 8pm to celebrate the one-year anniversary of their Red Bank clinic.
"We are so thankful for the support we have received from our clients, other local businesses and the wonderful city of Red Bank," stated Jennifer June, President of Evolve Med Spa. "Hosting this celebration is a way for us to show gratitude for the loyalty and support that helped us to become the region's provider of choice for skin rejuvenation, injectables, body contouring and laser hair removal. This event will feature incredible promotions as well as raffles and gifts for attendees."
Evolve Med Spa has established itself as an industry leader in the field of aesthetics. Since its initial location opened in June of 2020, the brand has become known for its commitment to helping clients look and feel their best. They focus on individualized treatment plans, natural-looking results and an exceptional experience. Evolve Med Spa of Red Bank opened early 2022, and this clinic has quickly become a regional favorite.
Some of the featured promotions at Evolve Med Spa's Anniversary Event include:
Skin Rejuvenation: 20% off of all Morpheus8 RF Microneedling packages and Hydrafacials, and $200 off packages of 3 VI Peels.
Body Contouring: 50% off EmSculpt Neo packages (of 8 or more cycles), and up to $3000 off of non-surgical, injectable Butt Lifts.
Laser Hair Removal: Buy one package, get second 50% off.
Injectables: $200 off of each syringe of filler and reduced-price wrinkle-relaxer toxins, including $10/unit Botox and Dysport and $7/unit Xeomin and Jeuveau.
Event will be held at Evolve Med Spa-Red Bank at 12 Broad Street on March 23, 2023, from 10am to 8pm. To RSVP or for more details, visit their event page here or call 800-867-8015.
About Evolve Med Spa
Evolve Med Spa is an award-winning destination for aesthetic services. With clinics throughout New York, New Jersey and Maryland, Evolve Med Spa has become a top provider of skin rejuvenation, injectables, laser hair removal, body contouring, hair regrowth and weight loss services.
Contact Information:
Judy O’Gorman Alvarez
Editor, Two River Times [email protected]
732-219-5788
DECATUR, Ga., March 20, 2023 (Newswire.com)
-
After the overwhelming success of the March on Clairemont during the 2022-2023 school year, Clairemont Elementary School committed to expanding efforts to include the entire Decatur community. It is with extreme excitement that the budding equity and social justice leaders at Clairemont Elementary School present March on Decatur. On Friday, March 31, 2023, at 9:30 AM, Clairemont Elementary will lead a march from 155 Erie Avenue that will culminate on the stairs of the Decatur History Center, where those gathered will hear from dynamic community leaders and student activists. The theme for the march is "Extinguishing the Isms."
"We are confident that support from our school community can and will bring attention to and boldly take steps to eliminate sexism, heterosexism, ableism, and racism," said Clairemont Elementary principal Dr. Curtis Armour. In the month leading up to the march, students will participate in an age-appropriate curriculum that focuses on each of these "isms." At the conclusion of the experience, students will choose the social justice issue that is most meaningful to them and create chants, posters and banners that demand change.
Also, The Clairemont Elementary School Equity Team, PTA/DEI Committee, and the John R. Lewis Legacy Institute will host a Conversation of Understanding, an initiative to raise awareness, educate, and unite the Clairemont community. The event will take place on Wednesday, April 12, 2023, from 5:30 PM- 7 PM in the Clairemont Auditorium. The moderators for the evening will be Mr. Garry Lowe and Mrs. Chanell Huff-Cox.
The Conversation Champions (Panelists) will tackle the rich and complex topic of diversity and inclusion by bravely sharing challenging personal experiences. They will highlight biases and stereotypes they have encountered, and how these difficult situations impacted them. Speakers will also share practical tips on how we all can act in a more inclusive manner. "We will also emphasize allyship among our residents. More specifically, identifying opportunities to be an effective ally, explaining what allyship looks like on a day-to-day basis and highlighting the positive impact that allies can have on under-represented communities," said JRLLI Executive Director Jerrick Lewis.
The John R. Lewis Legacy Institute, Inc. (JRLLI) is a nonprofit organization comprised of members of Congressmen Lewis' immediate family, whose mission is to promote diversity, support civil rights education, and engage in community service projects, including but not limited to Social Justice, Equity in Education, and Health Awareness, enabling future generations to continue the legacy of good and necessary trouble.
Contact Information:
Dr. Curtis Armour
Principal, Clairemont Elementary School [email protected]
404-370-4450
Once Jenna Ortega was hard at work playing the title character on Netflix’s Addams Family series Wednesday, she became so dedicated to making sure the title character came off just right that she would even change lines from the way they were written in the scripts. But during an interview with the UK’s Times, she revealed that she initially passed on the chance to star in Wednesday.
Ortega told the Times (as reported by Deadline), “I got the email, passed on it. I had done so much TV in my life, all I’ve ever wanted to do is film. I was scared that by signing on to another television show it could prevent me from doing other jobs I really wanted and cared about.“
It was the involvement of Tim Burton, who executive produced the series and directed four of the first season’s eight episodes, that convinced Ortega to give Wednesday a try. Eventually. “Tim is such a legend, and we just happened to get along very well. But even then I said, ‘Ah, no — I think I’m OK,’ a couple [more] times.” Ortega and Burton got along so well, they might end up working together again on Beetlejuice 2. And Wednesday turned out to be one of the biggest hit shows on Netflix.
Wednesday is described as
a comedic, supernaturally-infused coming-of-age series that follows the teenage girl’s years as a student at Nevermore Academy, where she attempts to master her emerging psychic ability, thwart a monstrous killing spree that has terrorized the town, and solve a mystery that embroiled her parents 25 years ago — all while navigating her new relationships at Nevermore. Snap snap.
Ortega is joined in the cast by Isaac Ordonez as Pugsley and Luis Guzmán and Catherine Zeta-Jones as Gomez and Morticia. Also on the show are Riki Lindhome as Wednesday’s therapist Dr. Valerine Kinbot; Joy Sunday as Siren Nevermore student Bianca Barclay; Emma Myers as Wednesday’s sunny roommate Enid Sinclair; Hunter Doohan as townie Tyler Galpin; Moosa Mostafa as quirky Nevermore student Eugene Otinger; Georgie Farmer as awkward and shy Nevermore student Ajax Petropolus; Naomi J. Ogawa as vampire Nevermore student Yoko Tanaka; Percy Hynes White as supernaturally artistic Nevermore student Xavier Thorpe; Jamie McShane as Sheriff Donovan Galpin, Tyler’s father, who has a vendetta against Gomez; Gwendoline Christie as Larissa Weems, “the principal of Nevermore Academy who still has an axe to grind with her former classmate Morticia Addams”; Victor Dorobantu as Thing, the non-verbal disembodied hand; George Burcea as Lurch; Tommie Earl Jenkins as Mayor Walker; Iman Marson as Lucas Walker; William Houston as Joseph Crackstone; Luyanda Unati Lewis-Nyawo as Deputy Santiago; Oliver Watson as Kent; Calum Ross as Rowan; and Johnna Dias Watson as Divina.
Thora Birch had signed on to play a character named Tamara Novak, “Wednesday’s dorm mother and the only ‘normie’ on staff at Nevermore Academy, with a focus on all things botanical.” Sadly, due to a family illness, Birch had to leave the production in Romania and return to the United States before filming was complete. Christina Ricci, who previously played Wednesday herself in the live-action feature films The Addams Family and The Addams Family Values, replaced Birch, taking on the role of Marilyn Thornhill.
Are you glad Ortega finally decided to sign on to play Wednesday? Share your thoughts on the Netflix series by leaving a comment below.
Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities.
PHILADELPHIA, March 20, 2023 (Newswire.com)
-
Senzo Health Limited (London, UK) ("Senzo") and Abingdon Health PLC (York, UK) ("Abingdon Health") are pleased to announce the signing of a strategic partnership agreement.
Under the terms of the partnership, Abingdon Health will support Senzo by providing contract development and manufacturing ("CDMO") services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilizing Senzo's cutting-edge ALF platform.
Senzo is a leading innovator in the rapid diagnostics testing market, with its revolutionary lateral flow technology delivering the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost. Senzo Health's technology is initially being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests. However, there is a wide range of applications across clinical, animal health, food, plant pathogen and environmental testing that would benefit from the strengths of Senzo's platform technology. This strategic partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.
Abingdon Health is a leading lateral flow CDMO offering its services to an international customer base across a range of industry sectors. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing, from "idea to commercial success". All projects are managed through Abingdon Health's quality management system, and its services include feasibility, optimization, technical transfer, manufacturing, regulatory and commercial support. Its UK-based automated manufacturing operations are capable of producing tens of millions of lateral flow tests per annum.
Jeremy Stackawitz, CEO of Senzo Health, commented, "This new partnership, with such an established, innovative, and trusted group as Abingdon, is a terrific opportunity for Senzo as we seek to expand the tests being developed and brought to market on our game-changing ALF platform. Collaborating with Abingdon creates a valuable synergy for customers looking to bring innovative, high-performance lateral flow products to market, and we're extremely eager to get to work on the first assays."
Chris Yates, CEO of Abingdon Health, commented, "We are really excited to be working with Senzo and supporting them in leveraging their cutting-edge lateral flow platform technology across multiple applications. We believe this strategic partnership agreement provides Senzo Health and its customers with access to Abingdon's best-in-class CDMO service to enable accelerated product development and time to market."
About Senzo: Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded to utilize novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com
About Abingdon Health: Abingdon Health is a leading lateral flow contract development and manufacturing organization ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing, from "idea to commercial success." www.abingdonhealth.com
Contact Information:
Alex Mohacs
Sales & Marketing [email protected]
![Shazam: Fury of the Gods TV spot spoils big cameo appearance much to the chagrin of the director [SPOILERS]](https://www.joblo.com/wp-content/uploads/2023/03/shazam-2-01062023-3-4bd961af8b9f408f91cbba03abe683fd-1024x538.jpg "Shazam: Fury of the Gods TV spot spoils big cameo appearance much to the chagrin of the director [SPOILERS]")
